Clinical trials
Phase 1 Wilms Tumor trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
57 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 4 |
| 2002 | 1 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 36 |
| Recruiting | 8 |
| Active, not recruiting | 5 |
| Terminated | 4 |
| Unknown status | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 10 |
| Baylor College of Medicine | 4 |
| National Institutes of Health Clinical Center (CC) | 4 |
| Emory University | 3 |
| Seattle Children's Hospital | 3 |
| AeRang Kim | 2 |
| Children's Oncology Group | 2 |
| City of Hope Medical Center | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| New York Medical College | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Wilms Tumor | 57 |
| Neuroblastoma | 41 |
| Rhabdomyosarcoma | 28 |
| Sarcoma | 28 |
| Osteosarcoma | 25 |
| Sarcoma, Ewing | 22 |
| Neoplasms | 19 |
| Medulloblastoma | 17 |
| Rhabdoid Tumor | 15 |
| Astrocytoma | 13 |
Trials
Showing 1 to 25 of 57. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.